Levine James E. 4/A
4/A · Cidara Therapeutics, Inc. · Filed Mar 23, 2020
Insider Transaction Report
Form 4/AAmended
Levine James E.
Chief Financial Officer
Transactions
- Purchase
Common Stock
2019-09-24$1.91/sh+30,000$57,240→ 30,000 total
Footnotes (2)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.90 to $1.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
- [F2]On September 26, 2019, the reporting person filed a Form 4 which inadvertently reported that, following his open market purchase, he held 205,000 shares of the issuer's common stock. In fact, as reported in this amendment, the reporting person directly owned 30,000 shares of common stock.